[go: up one dir, main page]

PE20160520A1 - Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion - Google Patents

Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion

Info

Publication number
PE20160520A1
PE20160520A1 PE2016000096A PE2016000096A PE20160520A1 PE 20160520 A1 PE20160520 A1 PE 20160520A1 PE 2016000096 A PE2016000096 A PE 2016000096A PE 2016000096 A PE2016000096 A PE 2016000096A PE 20160520 A1 PE20160520 A1 PE 20160520A1
Authority
PE
Peru
Prior art keywords
granules
pharmaceutical composition
preparation process
rifapentine
coated tablet
Prior art date
Application number
PE2016000096A
Other languages
English (en)
Inventor
Kumar Shakti
Kumar Ramesh
Prasad Kum
Prajapati Dilip
Khullar Praveen
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51211797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160520(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20160520A1 publication Critical patent/PE20160520A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a una composicion farmaceutica oral de dosis fija para uso en el tratamiento de la tuberculosis, comprendiendo dicha composicion farmaceutica oral: a) granulos que comprenden isoniazid y al menos un excipiente intragranular, b) granulos que comprenden rifapentina y al menos un excipiente intragranular, y c) al menos un excipiente extragranular, y a su proceso de preparacion
PE2016000096A 2013-07-26 2014-07-22 Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion PE20160520A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3341CH2013 2013-07-26

Publications (1)

Publication Number Publication Date
PE20160520A1 true PE20160520A1 (es) 2016-05-31

Family

ID=51211797

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000096A PE20160520A1 (es) 2013-07-26 2014-07-22 Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion

Country Status (18)

Country Link
US (1) US20160158157A1 (es)
EP (1) EP3024443A1 (es)
JP (1) JP6461142B2 (es)
CN (1) CN105407875A (es)
AU (1) AU2014295098B2 (es)
CA (1) CA2918827A1 (es)
CL (1) CL2016000182A1 (es)
EC (1) ECSP16005208A (es)
HK (1) HK1218862A1 (es)
IL (1) IL243368A0 (es)
MX (1) MX2016001154A (es)
PE (1) PE20160520A1 (es)
PH (1) PH12016500120A1 (es)
RU (1) RU2682178C2 (es)
SG (2) SG11201510730UA (es)
TW (1) TWI651084B (es)
WO (1) WO2015011161A1 (es)
ZA (1) ZA201600109B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160245A1 (es) 2013-07-26 2016-05-10 Sanofi Sa Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion
RU2672879C2 (ru) 2013-07-26 2018-11-20 Санофи Противотуберкулезная композиция, содержащая рифампицин, изониазид, этамбутол и пиразинамид, и способ ее получения
CN114306247A (zh) * 2020-09-27 2022-04-12 江苏先声药业有限公司 一种含利福喷汀药物组合物及其制备方法
CN115944638A (zh) * 2022-12-26 2023-04-11 卓和药业集团股份有限公司 一种利福喷丁和左氧氟沙星的复方双层片

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1217912A (zh) * 1997-11-26 1999-06-02 岑冠新 复方利福喷丁制剂及制备方法
TR200200966T1 (tr) * 2000-08-09 2002-09-23 Panacea Biotec Limited Tüberkülöz ilaçlarının yeni farmasötik terkipleri ve hazırlanma prosesleri
WO2002087547A1 (en) * 2001-04-27 2002-11-07 Lupin Limited An improved process for preparation of four-drug anti-tubercular fixed dose combination
US20050059719A1 (en) * 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US20090295921A1 (en) * 2005-10-12 2009-12-03 Pioneer Corporation Vehicle-mounted photographing device and method of measuring photographable range of vehicle-mounted camera
CN1857280A (zh) * 2006-04-11 2006-11-08 济南帅华医药科技有限公司 一种复方抗结核药物缓释制剂
KR101197277B1 (ko) * 2009-02-05 2012-11-05 (주) 벡스코아 경구용 결핵의 치료용 또는 예방용 고형 제형
US8470365B2 (en) * 2010-07-29 2013-06-25 Taiwan Biotech Co., Ltd. Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom

Also Published As

Publication number Publication date
MX2016001154A (es) 2016-04-29
PH12016500120A1 (en) 2016-04-25
ZA201600109B (en) 2017-04-26
TW201605442A (zh) 2016-02-16
RU2016106384A (ru) 2017-08-29
SG10201800447UA (en) 2018-02-27
JP6461142B2 (ja) 2019-01-30
CN105407875A (zh) 2016-03-16
HK1218862A1 (zh) 2017-03-17
SG11201510730UA (en) 2016-01-28
IL243368A0 (en) 2016-02-29
CL2016000182A1 (es) 2016-06-24
AU2014295098B2 (en) 2019-07-11
US20160158157A1 (en) 2016-06-09
RU2016106384A3 (es) 2018-05-31
WO2015011161A1 (en) 2015-01-29
CA2918827A1 (en) 2015-01-29
RU2682178C2 (ru) 2019-03-15
ECSP16005208A (es) 2017-02-24
JP2016539109A (ja) 2016-12-15
AU2014295098A1 (en) 2016-02-11
EP3024443A1 (en) 2016-06-01
TWI651084B (zh) 2019-02-21

Similar Documents

Publication Publication Date Title
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CY1122387T1 (el) Διπλης χρησης δισκια στοματικης φαρμακευτικης συνθεσης θειικων αλατων και μεθοδοι χρησης αυτων
CR20120549A (es) Composiciones farmacèuticas que comprenden hidromorfona y naloxona
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
MX2020004107A (es) Tabletas de deferiprona de liberacion retrasada y metodos de uso de las mismas.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
BR112016007031A8 (pt) composição farmacêutica oral sólida, processo para preparar a composição farmacêutica oral sólida, e uso de uma composição farcêutica oral sólida
TR201310724A2 (tr) Linagliptinin farmasotik formulasyonları.
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
UY37413A (es) Formulaciones de liberación inmediata de oprozomib
UY37518A (es) Formas de dosificación de liberación modificada gastroretentivas para oprozomib y proceso para su fabricación
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
MX2015011099A (es) Composiciones farmaceuticas de donepezilo que tienen un perfil de disolución in vitro o parámetros farmacocinéticos específicos.
IN2013MU02110A (es)
IN2013MU02286A (es)
AR099971A1 (es) Forma de dosificación unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolítico que comprende darunavir y ritonavir